Cargando…
OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides
This white paper summarizes the recommendations of the absorption, distribution, metabolism, and excretion (ADME) Subcommittee of the Oligonucleotide Safety Working Group for the characterization of absorption, distribution, metabolism, and excretion of oligonucleotide (ON) therapeutics in nonclinic...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561745/ https://www.ncbi.nlm.nih.gov/pubmed/37590469 http://dx.doi.org/10.1089/nat.2023.0011 |
_version_ | 1785117987120873472 |
---|---|
author | Berman, Cindy L. Antonsson, Madeleine Batkai, Sandor Bosgra, Sieto Chopda, Girish R. Driessen, Wouter Foy, Jeffrey Hassan, Chopie Hu, Xiao Shelley Jang, Hyun Gyung Meena, Sanseverino, Mark Thum, Thomas Wang, Yanfeng Wild, Martin Wu, Jing-Tao |
author_facet | Berman, Cindy L. Antonsson, Madeleine Batkai, Sandor Bosgra, Sieto Chopda, Girish R. Driessen, Wouter Foy, Jeffrey Hassan, Chopie Hu, Xiao Shelley Jang, Hyun Gyung Meena, Sanseverino, Mark Thum, Thomas Wang, Yanfeng Wild, Martin Wu, Jing-Tao |
author_sort | Berman, Cindy L. |
collection | PubMed |
description | This white paper summarizes the recommendations of the absorption, distribution, metabolism, and excretion (ADME) Subcommittee of the Oligonucleotide Safety Working Group for the characterization of absorption, distribution, metabolism, and excretion of oligonucleotide (ON) therapeutics in nonclinical studies. In general, the recommended approach is similar to that for small molecule drugs. However, some differences in timing and/or scope may be warranted due to the greater consistency of results across ON classes as compared with the diversity among small molecule classes. For some types of studies, a platform-based approach may be appropriate; once sufficient data are available for the platform, presentation of these data should be sufficient to support development of additional ONs of the same platform. These recommendations can serve as a starting point for nonclinical study design and foundation for discussions with regulatory agencies. |
format | Online Article Text |
id | pubmed-10561745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-105617452023-10-10 OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides Berman, Cindy L. Antonsson, Madeleine Batkai, Sandor Bosgra, Sieto Chopda, Girish R. Driessen, Wouter Foy, Jeffrey Hassan, Chopie Hu, Xiao Shelley Jang, Hyun Gyung Meena, Sanseverino, Mark Thum, Thomas Wang, Yanfeng Wild, Martin Wu, Jing-Tao Nucleic Acid Ther Issues in Development This white paper summarizes the recommendations of the absorption, distribution, metabolism, and excretion (ADME) Subcommittee of the Oligonucleotide Safety Working Group for the characterization of absorption, distribution, metabolism, and excretion of oligonucleotide (ON) therapeutics in nonclinical studies. In general, the recommended approach is similar to that for small molecule drugs. However, some differences in timing and/or scope may be warranted due to the greater consistency of results across ON classes as compared with the diversity among small molecule classes. For some types of studies, a platform-based approach may be appropriate; once sufficient data are available for the platform, presentation of these data should be sufficient to support development of additional ONs of the same platform. These recommendations can serve as a starting point for nonclinical study design and foundation for discussions with regulatory agencies. Mary Ann Liebert, Inc., publishers 2023-10-01 2023-10-03 /pmc/articles/PMC10561745/ /pubmed/37590469 http://dx.doi.org/10.1089/nat.2023.0011 Text en © Cindy L. Berman et al., 2023; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by/4.0/This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Issues in Development Berman, Cindy L. Antonsson, Madeleine Batkai, Sandor Bosgra, Sieto Chopda, Girish R. Driessen, Wouter Foy, Jeffrey Hassan, Chopie Hu, Xiao Shelley Jang, Hyun Gyung Meena, Sanseverino, Mark Thum, Thomas Wang, Yanfeng Wild, Martin Wu, Jing-Tao OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides |
title | OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides |
title_full | OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides |
title_fullStr | OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides |
title_full_unstemmed | OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides |
title_short | OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides |
title_sort | oswg recommended approaches to the nonclinical pharmacokinetic (adme) characterization of therapeutic oligonucleotides |
topic | Issues in Development |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561745/ https://www.ncbi.nlm.nih.gov/pubmed/37590469 http://dx.doi.org/10.1089/nat.2023.0011 |
work_keys_str_mv | AT bermancindyl oswgrecommendedapproachestothenonclinicalpharmacokineticadmecharacterizationoftherapeuticoligonucleotides AT antonssonmadeleine oswgrecommendedapproachestothenonclinicalpharmacokineticadmecharacterizationoftherapeuticoligonucleotides AT batkaisandor oswgrecommendedapproachestothenonclinicalpharmacokineticadmecharacterizationoftherapeuticoligonucleotides AT bosgrasieto oswgrecommendedapproachestothenonclinicalpharmacokineticadmecharacterizationoftherapeuticoligonucleotides AT chopdagirishr oswgrecommendedapproachestothenonclinicalpharmacokineticadmecharacterizationoftherapeuticoligonucleotides AT driessenwouter oswgrecommendedapproachestothenonclinicalpharmacokineticadmecharacterizationoftherapeuticoligonucleotides AT foyjeffrey oswgrecommendedapproachestothenonclinicalpharmacokineticadmecharacterizationoftherapeuticoligonucleotides AT hassanchopie oswgrecommendedapproachestothenonclinicalpharmacokineticadmecharacterizationoftherapeuticoligonucleotides AT huxiaoshelley oswgrecommendedapproachestothenonclinicalpharmacokineticadmecharacterizationoftherapeuticoligonucleotides AT janghyungyung oswgrecommendedapproachestothenonclinicalpharmacokineticadmecharacterizationoftherapeuticoligonucleotides AT meena oswgrecommendedapproachestothenonclinicalpharmacokineticadmecharacterizationoftherapeuticoligonucleotides AT sanseverinomark oswgrecommendedapproachestothenonclinicalpharmacokineticadmecharacterizationoftherapeuticoligonucleotides AT thumthomas oswgrecommendedapproachestothenonclinicalpharmacokineticadmecharacterizationoftherapeuticoligonucleotides AT wangyanfeng oswgrecommendedapproachestothenonclinicalpharmacokineticadmecharacterizationoftherapeuticoligonucleotides AT wildmartin oswgrecommendedapproachestothenonclinicalpharmacokineticadmecharacterizationoftherapeuticoligonucleotides AT wujingtao oswgrecommendedapproachestothenonclinicalpharmacokineticadmecharacterizationoftherapeuticoligonucleotides |